Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Kymriah becomes first CAR T available on NHS England

September 4, 2018 11:06 PM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) said it has reached an agreement with NHS England to make Kymriah tisagenlecleucel available in England, which the agency said marks Europe's first full access deal for a CAR T therapy.

NHS access to Kymriah is limited to patients under 25 years old with B cell acute lymphoblastic leukemia (ALL) that are refractory, in relapse post-transplant or in second or later relapse...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Novartis AG

BCIQ Target Profiles

CD19